General Information
Drug ID
DR00657
Drug Name
Cholic acid
Synonyms
(R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; 3,7,12-Trihydroxycholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; BHQCQFFYRZLCQQ-OELDTZBJSA-N; CHEBI:16359; CHEMBL205596; Cholalic acid; Cholalin; Cholic acid [USAN]; Cholic acid, 5beta-; Cholsaeure; Colalin; G1JO7801AE; HSDB 982; NSC-6135; NSC6135; UNII-G1JO7801AE; cholate
Drug Type
Small molecular drug
Indication Peroxisomal disorders [ICD11: 5C57.0] Approved [1]
Synthesis disorders [ICD11: 5C52.10] Approved [1]
Structure
3D MOL 2D MOL
Formula
C24H40O5
Canonical SMILES
CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C
InChI
InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1
InChIKey
BHQCQFFYRZLCQQ-OELDTZBJSA-N
CAS Number
CAS 81-25-4
Pharmaceutical Properties Molecular Weight 408.6 Topological Polar Surface Area 98
Heavy Atom Count 29 Rotatable Bond Count 4
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 5
XLogP
3.6
PubChem CID
221493
PubChem SID
11110315 , 14757556 , 15277848 , 17422064 , 24423691 , 24423929 , 24892356 , 24893153 , 26717723 , 26717726 , 26717727 , 26737120 , 26737126 , 26737128 , 26750105 , 26750407 , 26750412 , 26750415 , 26750420 , 26750424 , 30424718 , 3135999 , 3963 , 4266387 , 46507063 , 47193710 , 47662491 , 49700787 , 50452100 , 53787750 , 53789207 , 56313736 , 56437567 , 56437568 , 57399957 , 584143 , 607109 , 72129 , 7886587 , 81067251 , 81091088 , 8145669 , 822057 , 841391 , 85279435 , 85285851 , 85285861 , 85285865 , 85285871 , 9376190
ChEBI ID
CHEBI:16359
TTD Drug ID
D0OR2L
DT(s) Transporting This Drug ASBT Transporter Info Apical sodium-dependent bile acid transporter Substrate [2]
BCRP Transporter Info Breast cancer resistance protein Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [5]
OATP1A2 Transporter Info Organic anion transporting polypeptide 1A2 Substrate [6]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [7]
References
1 Cholic acid was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1):G157-69.
3 Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
4 Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75.
5 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
6 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
7 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.